Egypt’s HoldiPharma eyes 11.5% surge in net profit within FY2017/18

Egyptian Holding Company for Pharmaceuticals (HoldiPharma) says it targets an 11.5 percent increase in net profit to reach 145 million Egyptian pounds ($8 million) within the financial year 2017/2018.

The company also plans to boost revenues by 7.5 percent to register 260 million pounds within the financial year 2017/2018.

Mohamed Wanees, HoldiPharma’s chairman, said that the affiliates seek to increase its activity revenues by 47.8 percent to around 16 billion pounds within the next financial year.